Dr. Mark Miller Joins bioMérieux as Chief Medical Officer
World-leading expert on infectious disease prevention and control toenhance medical value of bioMérieux's solutions
Marcy l'Étoile, France (PRWEB) November 01, 2012
bioMérieux, a world leader in in vitro diagnostics, announces the arrival of Dr. Mark Miller in the newly created role of Chief Medical Officer. Dr. Miller is also a member of the bioMérieux Management Committee and heads the Company's Biomarkers department, Clinical Affairs group and Medical Affairs group.
A world-renowned medical clinician, researcher and microbiologist, Mark Miller is certified in Internal Medicine, Infectious Diseases, and Clinical Microbiology. He is also a Professor of Medicine at McGill University. Before joining bioMérieux, for over 15 years, he was the Head of Infectious Diseases, the Chair of Infection Prevention and Control, as well as the Chief of Clinical Microbiology at the Jewish General Hospital in Montreal, Canada. He is the author of over 120 scientific publications, over 140 abstracts and has conceived or conducted more than 60 large-scale research projects in the complex field of infectious diseases.
Dr. Miller is regarded to be one of the world's leading experts on the bacterium, Clostridium difficile, a leading cause of healthcare-associated infections.
“Looking to the future, the added medical value and the ratio between the cost and clinical benefit of diagnostics will become central issues,” said Jean-Luc Belingard, bioMérieux Chief Executive Officer. “I feel very fortunate to welcome Dr. Mark Miller to our team. As the world leader in microbiology, it is of paramount importance to have one of the foremost experts in our field to reinforce the medical scope of our solutions and to help guide our technological and scientific choices.”
Reinforcing the added medical value of its diagnostic solutions is one of bioMérieux's two main product development goals, along with improving laboratory efficiency. In particular, in clinical microbiology, bioMérieux recently launched its FMLA® (Full Microbiology Lab Automation) range, comprising solutions to help labs focus on providing results that are more clinically relevant faster. In 2013, bioMérieux will launch two customer-centric, innovative platforms to expand this offer: a new blood culture system and an incubator integrating imaging technologies. In the immunoassays field, where bioMérieux focuses on high medical value tests, Mark Miller's contribution will also be of critical importance for selecting novel biomarkers.
Mark Miller will be based at the bioMérieux headquarters, in France. He will continue to direct an Infectious Diseases Research Unit at the Jewish General Hospital in Montreal, with an emphasis on studying healthcare-associated infections, and will also remain a professor at McGill University.
Dr. Miller will enhance a network of leading international clinicians and biologists and expand bioMérieux's clinical studies and partnerships with universities and hospitals. He joins bioMérieux's team of scientific experts, including Alex van Belkum, Ph.D., Ph.D., bioMérieux's Corporate Vice President R&D Microbiology and Professor of Molecular Microbiology at Erasmus University, Rotterdam, and Wm. Michael Dunne, Jr., Ph.D., bioMérieux's Executive Director, R&D Microbiology North America, Adjunct Professor at Washington University School of Medicine and Duke University School of Medicine, and senior editor of the Journal of Clinical Microbiology.
Advancing Diagnostics to Improve Public Health
A world leader in the field of in vitro diagnostics for over 45 years, bioMérieux is present in more than 150 countries through 40 subsidiaries and a large network of distributors. In 2011, revenues reached €1.427 billion with 87% of sales outside of France.
bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agrifood, pharmaceutical and cosmetic products.
Corporate website: http://www.biomerieux.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/11/prweb10085370.htmView Comments and Join the Discussion!